Crystalline alpha,alpha-disubstituted amino acids for stable polypeptide synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods for producing α, α-disubstituted amino acids are limited by the availability of crystalline forms, which restricts their use due to pre-made solutions that are environmentally unfriendly, degrade quickly, and have limitations in chemical reactions and shipping capacity.
Innovation Solution
The development of crystalline compounds and salts of Formula (I) and their methods of preparation, including crystallization from specific solvents and purification techniques, to produce stable and high-purity α, α-disubstituted amino acids and their salts, enabling the synthesis of stapled and stitched polypeptides for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If pre-made solutions of alkene α,α-disubstituted amino acids are used, then availability is improved, but stability deteriorates due to enhanced degradation rate
Solution Approach 1:
The patent applies phase transition by converting the amino acids from liquid solution form to solid crystalline form. This phase change from liquid to solid state fundamentally alters the stability profile, reducing degradation rates while maintaining availability through controlled crystallization processes described in the patent.
Solution Approach 2:
The patent changes the physical state parameter from liquid to solid, and modifies chemical composition parameters by incorporating deuterium or halogen atoms at specific positions. These parameter changes collectively improve stability while preserving the functional availability of the amino acids for peptide synthesis.
2Ease of operation
If pre-made solutions are used, then ease of use is improved, but environmental friendliness deteriorates
Solution Approach 1:
By transitioning from liquid solution to solid crystalline form, the patent reduces the volume of solvent required for transport and storage. This phase change enables more concentrated formulations with less packaging material, directly addressing environmental concerns associated with solution-based distributions.
3Ease of operation
If pre-made solutions are used, then availability is improved, but productivity deteriorates due to limited shipping capacity per unit volume
Solution Approach 1:
The solid crystalline form enables higher density packing compared to liquid solutions. The patent describes crystalline structures that can be stored and transported in compact forms, increasing the effective shipping capacity and amount of active ingredient deliverable per unit volume.
4Ease of operation
If pre-made solutions are used, then availability is improved, but chemical reactivity deteriorates due to limited chemical reactions available
Solution Approach 1:
The patent modifies molecular parameters by introducing deuterium or halogen substitution at specific positions (R1, R2, or R3 groups). These parameter changes enhance chemical versatility and reactivity, enabling the crystalline amino acids to participate in a broader range of chemical reactions while maintaining their availability for peptide synthesis applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of α, α-disubstituted amino acids and their salts facilitate the production of stable polypeptides that can stabilize secondary structures, such as alpha helices, and are useful for treating and preventing diseases, including cancer, with improved chemical and enantiomeric purity.
Implementation Method 1
crystallization from specific solvents and purification techniques
Implementation Method 2
crystallization from specific solvents
Data Source
AI summary
Provided are crystalline α, α-disubstituted amino acids and their crystalline salts containing a terminal alkene on one of their side chains, as well as optionally crystalline halogenated and deuterated analogs of the α, α-disubstituted amino acids and their salts; methods of making these, and methods of using these.